Shield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.
Shield Therapeutics is a patient-focused, commercial-stage pharmaceutical company on a mission to improve the lives of people suffering from iron deficiency, enabling them to enjoy the things that make a difference in their everyday lives. Its lead medicine ACCRUFeR® (ferric maltol), is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish, based in the UK, assisted Shield Therapeutics in securing its funding package.
Talk to the deal team
Related deals
Gewiss S.p.A. has completed a mandatory public tender offer for Beghelli S.p.A.
Gewiss S.p.A. has successfully finalized a mandatory public tender offer for Beghelli S.p.A.
Learn moreiwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.
Learn moreBezeq Online has been acquired by One Software Technologies
Bezeq Online has been acquired by ONE Software Technologies Ltd., enabling ONE Technologies to offer innovative solutions through full integration of advanced technology, real-time data analysis and proven service capabilities nationwide. ONE Technologies’ goal is to develop the next generation of service solutions, including AI-based tools, automation, multi-channel digital services and advanced CRM systems, all designed to deliver a continuous, accurate and effective customer experience.
Learn more